Generic Name: doravirine + tenofovir disoproxil fumarate + lamivudine
Drug Class: Single-Tablet Regimens
Company: Merck & Company
Approval Status: Approved
Generic Version Available: No
Experimental Code: MK-1439A
The U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents lists Delstrigo as a recommended initial HIV treatment regimens in certain clinical situations.
Delstrigo is single-tablet regimen for HIV. It contains three different types of HIV drugs: one non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs). It was approved by the U.S. Food and Drug Administration in August 2018, for use by people starting HIV treatment for the first time.
Delstrigo is a single-tablet regimen containing Pifeltro (doravirine) and generic versions of tenofovir disoproxil fumarate and lamivudine.
Adult Dose: One tablet once a day. Each tablet contains 100mg doravirine + 300mg tenofovir disoproxil fumarate + 300mg lamivudine.
For adults taking the antibiotic rifabutin, Delstrigo should be taken once a day, followed by one tablet of Pifeltro (darunavir) approximately 12 hours later.
Pediatric Dose: N/A
Dosing Info: This is a complete one-pill, once-daily drug regimen. Take with or without food.
Common side effects associated with Delstrigo inlcude dizziness, nausea, and abnormal dreams.
For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Delstrigo or may require dose adjustments, consult the Delstrigo package insert: https://www.merck.com/product/usa/pi_circulars/d/delstrigo/delstrigo_pi.pdf
Before taking this medication, tell your doctor if you have kidney disease or liver disease (including hepatitis B). In addition, tell your doctor if you are pregnant or planning to become pregnant; if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.
Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Last Reviewed: May 21, 2019